Osteoarthritis market value to triple by 2024 from 2014 level, says report

20 September 2016

The osteoarthritis market across the world’s seven major pharma markets will be worth nearly $10.5 billion by 2024, predicts research and consulting firm GlobalData.

In the company’s report on this treatment area, it is predicted that radical changes in this space will lead to its value tripling by 2024 compared to the 2014 level of $3.25 billion in the USA, France, Germany, Italy, Spain, the UK, and Japan.

That represents a compound annual growth rate of 17.8%, a rise that the report forecasts will be brought about by the launch of new biologics priced at a substantial premium to small-molecule therapies, and the arrival of drugs with novel mechanisms of action (MOAs) and disease-modifying effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK